BiotechTube

Imdusiran + Durvalumab

Phase 2Withdrawn
0 watching 0 views this week⚡ Active
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hepatitis B, Chronic

Conditions

Hepatitis B, Chronic

Trial Timeline

May 1, 2024 → Aug 1, 2024

NCT ID
NCT06245291

About Imdusiran + Durvalumab

Imdusiran + Durvalumab is a phase 2 stage product being developed by Arbutus Biopharma for Hepatitis B, Chronic. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT06245291. Target conditions include Hepatitis B, Chronic.

Hype Score Breakdown

Clinical
17
Activity
12
Company
5
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT06245291Phase 2Withdrawn

Competing Products

20 competing products in Hepatitis B, Chronic

See all competitors
ProductCompanyStageHype Score
VK2809 + PlacebosViking TherapeuticsPhase 2
47
TERN-501 + TERN-101Terns PharmaceuticalsPhase 2
49
TERN-101Terns PharmaceuticalsPhase 2
49
TERN-201Terns PharmaceuticalsPhase 1
30
IVA337 + IVA337 + PlaceboInventivaPhase 2
47
IVA337 + Placebo + EmpagliflozinInventivaPhase 2
47
IVA337 + PlaceboInventivaPhase 3
72
Pegasys® + Pegasys®Chugai PharmaceuticalApproved
85
peginterferon alfa-2a + rivavirinChugai PharmaceuticalPhase 3
77
SOF + COPEChugai PharmaceuticalPre-clinical
23
Colesevelam HclDaiichi SankyoPhase 2
52
ASP9831 + PlaceboAstellas PharmaPhase 2
52
FK788Astellas PharmaPhase 2
52
MK-2248MerckPhase 1
33
Interferon alfacon-1Astellas PharmaPhase 3
77
Pegylated Interferon + RibavirinAstellas PharmaApproved
85
Tacrolimus + steroids, monoclonal anti-IL2R antibodyAstellas PharmaPhase 2
52
Dolutegravir + Rlipivirine + GSK1265744ShionogiPhase 1
33
Dolutegravir + MethadoneShionogiPhase 1
33
Clevudine + AdefovirEisaiPhase 3
77

Other Products from Arbutus Biopharma

VBR + AB-729 + SOC NrtIPhase 2
47
Imdusiran (AB-729)Phase 2
47
ARB-001467Phase 2
47
AB-729 + Peg-IFNα-2aPhase 2
47
TKM-080301Phase 1/2
36